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There are many compelling reasons to
study mixed lineage leukemia (MLL)
fusion genes in human leukemia. From a
purely clinical perspective, the expres-
sion of MLL fusion proteins by leukemic
cells almost always confers a worse prog-
nosis. Such alterations are found in 80%
of acute lymphoblastic leukemias (ALLs)
and acute myeloid leukemias (AMLs) that
arise in infants, almost all cases of sec-
ondary AML that arise after treatment
with topoisomerase II inhibitors, and at
least 10% of de novo ALLs and AMLs in
children and adults. Of considerable fun-
damental importance is the opportunity
to elucidate the signaling pathways
usurped by chimeric MLL oncoproteins,
including those initiated by the direct
downstream targets of MLL, such as the
major HOX genes, which encode highly
conserved transcription factors with criti-
cal roles in both embryonic and
hematopoietic differentiation.
Identified by cloning human chromo-
some band 11q23 breakpoints, MLL was
shown to be the mammalian counterpart
of trithorax, the Drosophila gene that
encodes a nuclear regulatory protein
required for the maintenance of specific
spatial patterns of HOM-C gene expres-
sion induced during embryogenesis
(Schumacher and Magnuson, 1997).
Mammalian cells contain 39 different
major HOX genes, grouped in clusters
(HOXA to HOXD) on four separate chro-
mosomes, which share extensive homol-
ogy with the HOM-C genes of Drosophila
and play major roles in axial morphogen-
esis and patterning (Maconochie et al.,
1996). These relationships predict that
normal MLL, and possibly the leuke-
mogenic fusion proteins generated from
it by chromosomal translocation, might
function as epigenetic regulators of the
corresponding HOX genes in humans
and other mammals. This hypothesis
was shown to be correct in mice, in
which heterozygous germline inactiva-
tion of Mll resulted in homeotic transfor-
mations of the axial skeleton associated
with abnormalities in the maintenance,
but not the initiation, of Hoxa7 and Hoxc9
gene expression (Yu et al., 1995).
Moreover, HOX genes were shown to
have highly specific patterns of expres-
sion in subsets of murine and human
hematopoietic stem and progenitor cells
(Look, 1997; Sauvageau et al., 1994),
while multiple lines of evidence support-
ed a major role of dysregulated HOX
gene expression in leukemogenesis
(reviewed in Look, 1997). For example,
high levels of HOX gene expression are
a major component of the gene expres-
sion profiles that distinguish early B-lin-
eage leukemias with MLL fusion genes
from those transformed by other mecha-
nisms (Armstrong et al., 2002; Yeoh et
al., 2002). Also, comparative analysis of
the gene expression profiles of T- and
early B-lineage leukemias implicated
upregulation of a subset of major HOX
genes—HOXA9, HOXA10, and HOXC6—
and the MEIS1 HOX coregulator as the
central distinguishing feature of leukemic
transformation by MLL oncoproteins
(Ferrando et al., 2003). These findings
raise a critical question concerning the
oncogenicity of MLL: do chimeric MLL
oncoproteins act on target genes
through the same mechanisms exploited
by wild-type MLL or have they evolved
unique strategies?
Progress in dissecting normal HOX
gene regulation has provided valuable
clues to the requirements for leukemic
transformation by MLL fusion proteins.
Since HOX gene expression must not
only be maintained in specific subsets of
CD34+ hematopoietic stem and progeni-
tor cells but also must be downregulated
as lymphoid and myeloid cells mature in
the bone marrow (Sauvageau et al.,
1994), any mechanism of effective gene
regulation must accommodate both cri-
teria. This issue has been partially
addressed for wild-type Mll by showing
direct binding of the normal Mll protein,
as a component of a large multiprotein
supercomplex, to the Hoxa9 and Hoxc8
regulatory regions in chromatin immuno-
precipitation assays and by the demon-
stration that the SET domain of Mll is a
histone H3 (lysine 4)-specific methyl-
transferase whose activity is associated
with Hox gene activation (Milne et al.,
2002; Nakamura et al., 2002). Recent
studies have further demonstrated that
wild-type MLL is processed into two frag-
ments—a carboxy-terminal fragment
with strong transcriptional activation
properties and an amino-terminal frag-
ment with transcriptional repression
activity (Hsieh et al., 2003; Yokoyama et
al., 2002) (Figure 1).The C-terminal frag-
ment contains the SET domain and the
TAD domain, which possesses transcrip-
tional activation capacity. The N-terminal
fragment comprises a series of AT-hook
motifs that bind DNA; the SNL1 and
SNL2 regions, which mediate speckled
subnuclear localization; a CXXC region
with homology to a DNA methyltrans-
ferase that possesses transcriptional
repressor activity; and the PHD zinc fin-
ger domain, which is bisected by MLL
chromosomal translocations. Thus post-
translational cleavage of MLL may pro-
vide an on-off mechanism that would
resolve the seemingly contradictory
repressor and activator activities of MLL.
Recently, it was shown that Hoxa9-
deficient bone marrow cells could not be
transformed in vivo by transduction with
a retroviral MLL fusion gene construct
highly active in the leukemic transforma-
tion of normal mouse bone marrow cells,
providing the first direct evidence that
activation of Hoxa9 may be required for
leukemic transformation mediated by
MLL fusion proteins (Ayton and Cleary,
2003). A similar genetic approach was
used to show that Hoxa7 is also required
for full in vitro oncogenicity of the MLL
fusion protein. The N-terminal fragment
of MLL, which is consistently involved in
fusions with varied protein partners,
lacks a SET domain and therefore could
not be expected to facilitate transcription
through the normal route of histone
methylation (Milne et al., 2002).This sug-
gests that the mechanism(s) underlying
aberrant regulation of HOXA9 and other
downstream targets of MLL fusion pro-
teins may differ radically from that of nor-
mal MLL (see Figure 1).
So and coworkers, in this issue of
Cancer Cell, provide an intriguing piece
of the MLL oncoprotein/HOX gene puz-
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Turning on a dimer: New insights into MLL chimeras
In this issue of Cancer Cell, So et al. (2003) demonstrate a novel mechanism for the oncogenic activity of MLL chimeric pro-
teins. By providing coiled-coil or other dimerization domains, the cytoplasmic partners of MLL fusion proteins donate a
platform for MLL homodimerization, allowing recruitment of accessory factors needed to activate the critical downstream
targets, including selected subsets of the major HOX genes.
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zle, showing that simple dimerization of
MLL by a cytoplasmic fusion partner
(either GAS7 or AF1p) activates its tran-
scriptional and oncogenic properties.
These include upregulation of the murine
Hoxa7, a9, and a10 genes, as well as the
Hox cofactor gene Meis1, which other-
wise are repressed in differentiating
myeloid progenitors. This mechanism is
especially relevant in light of the remark-
able array of nuclear and cytoplasmic
proteins (more than 40 by last count) that
can fuse with MLL. Comparison of these
results with HOX gene expression pro-
files produced by MLL-ENL, which dis-
plays intrinsic transcriptional effector
activity, indicated similar effects for both
classes of MLL fusion proteins, suggest-
ing that the Hox gene specificity of MLL
fusion proteins may not be significantly
affected by the lack of classical transcrip-
tional effector domains in cytoplasmic
versus nuclear fusion partners.
Oligomerization of MLL through the
coiled-coil domains of the cytoplasmic
GAS7 and AF1p proteins helps to
explain how widely divergent fusion part-
ners might achieve the same end result,
leukemic transformation, but leaves
unresolved the critical issue of a mecha-
nism for dysregulation of HOX gene
expression. Wild-type MLL encodes a
histone methytransferase that has been
reported to assemble into a supercom-
plex (Nakamura et al., 2002) containing
several chromatin-modifying compo-
nents that can remodel, acetylate,
deacetylate, and methylate nucleosomal
histones. MLL normally maintains HOX
gene transcription in part by targeting
SET domain methyltransferase activity to
HOX gene promoters (Milne et al.,
2002), but this domain as well as the TAD
transcriptional activation domain are lost
by leukemogenic MLL fusion proteins.
Thus, So and coauthors suggest that
forced dimerization of MLL creates a
transcriptional activator complex capable
of stimulating HOX expression in the
absence of histone methylation. They
further propose that MLL dimerization
may lead to the inappropriate recruit-
ment of accessory factors required for
sustained expression of HOX genes.
Interestingly, this model may also
account for the oncogenicity of a class of
transforming “self-fusion” MLL proteins,
which arise through an intrachromoso-
mal tandem duplication of N-terminal
MLL sequences, effectively producing a
tethered homodimer of this region fused
to the remainder of the MLL coding
sequences (Schichman et al., 1994).
The elegant demonstration of a
novel mechanism whereby MLL fusion
proteins could engage HOX genes in
malignant transformation strengthens
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Figure 1. Different mechanisms of HOX gene
regulation by MLL proteins
A: Wild-type MLL is usually cleaved into N-ter-
minal and C-terminal moieties, but N-termi-
nal residues can also participate in
leukemogenic fusions with either nuclear
(activator) or cytoplasmic (dimerizer) pro-
teins. Putative functional domains are shown
in color and designated as follows: AT 1-3,
AT-hook DNA binding motifs 1, 2, and 3; SNL1
and 2, speckled nuclear localization signals 1
and 2; CxxC, cysteine-rich motif homologous
to DNA methyltransferase and MBDI; PHD 1-
3, PHD fingers 1, 2, and 3; TAD, transactiva-
tion domain; SET, histone methyltransferase
domain.
B: In gene regulation by wild-type MLL, the N-
terminal and C-terminal moieties cooperate
in a large multiprotein supercomplex that
can remodel, acetylate, deacetylate, and
methylate histones (gray circles, unmethylat-
ed histone; yellow, methylated) to regulate
HOX gene transcription. Wild-type MLL is
required for the maintenance of HOX gene
expression by hematopoietic stem and
progenitor cells, but mechanisms must also
exist that extinguish HOX gene expression as
myeloid and lymphoid cells differentiate.
C: Some chimeric MLL proteins with nuclear
fusion partners act as monomers to constitu-
tively activate HOX gene expression in
leukemic stem cells, while others with cyto-
plasmic partners (D) rely on forced homod-
imerization to constitutively activate HOX
gene transcription.
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the argument for selected HOX genes
being preferred targets of this class of
leukemogenic transcription factors. Once
the downstream targets of the vertebrate
HOX proteins are identified, both in
embryologic development and in leuke-
mogenesis, it should be possible to
expand on current models of HOX gene
involvement in the human leukemias,
hopefully yielding new targets for thera-
peutic intervention.
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Tumor cell breach of physiological barri-
ers defines the point in neoplastic growth
when medical intervention becomes infi-
nitely harder.The breach of such barriers
has often been associated with expres-
sion of one of more matrix metallopro-
teinases, a family of Zn-dependent
endopeptidases that collectively are
capable of cleaving virtually all extracel-
lular matrix substrates. In the July 11
issue of Cell, Hotary et al. (2003) demon-
strate that cancer cells rendered capable
of expressing a single proteinase, name-
ly the membrane bound matrix metallo-
proteinase-1 (MT1-MMP) (Sato et al.,
1994), acquire potent collagenolytic
activity that enables cell proliferation in a
three-dimensional collagen matrix or fib-
rin matrix and moreover enhances sub-
cutaneous growth of tumor cells in nude
mice. Remarkably, a similar effect is not
conferred by any of seven soluble matrix
metalloproteinases, including three
“classical” collagen-cleaving proteinases
(MMP-1, MMP-2, and MMP-13)
(Brinckerhoff and Matrisian, 2002;
Egeblad and Werb, 2002). Equally sur-
prising, the growth-promoting effect of
MT1-MMP was lost on planar, 2D sur-
faces or under circumstances where the
3D matrix is not degradable. The signifi-
cant difference between behavior in 2D
and 3D mirrors a previous observation
by Cukierman et al. (2001) on cell-matrix
adhesive properties.
Taken together, the observations in
the Hotary et al. paper have several
important implications. They support the
notion that pericellular interstitial col-
lagenolytic activity rests with a single
molecule—namely the tethered trans-
membrane collagen-cleaving member of
the MMP family (Brinckerhoff and
Matrisian, 2002; Egeblad and Werb,
2002) that alone is capable of conferring
collagen-degrading abilities to otherwise
incompetent cells. Although the predom-
inant paradigm for the role of MT1-MMP
in matrix degradation has been to act as
an activator of downstream-secreted
MMPs, Hotary et al. provide direct evi-
dence for an intrinsic collagenase activi-
ty of MT1-MMP. Whereas the lack of
impairment of collagen degradation in
several MMP knockout models could in
principle be ascribed to the obvious
redundancy of the system, MT1-MMP
depletion alone is sufficient to generate a
“collagen-indigestion” phenotype in the
mouse (Holmbeck et al., 1999).
Considering that MT1-MMP alone can
provide a tumor cell with invasiveness,
whereas secreted MMPs cannot, the
question arises whether additional teth-
ered MMPs can do it.
Hotary et al. moreover demonstrate
MT1-MMP: A collagenase essential for tumor cell invasive growth
The manuscript discussed in this preview describes that reconstituted three-dimensional extracellular matrices such as
fibrillar collagen and fibrin exert stringent territorial growth control on cells.The authors show that tumor cells are able to
escape the matrix-enforced growth control effect (entrapment) by pericellular proteolysis mediated by MT1-MMP, a mem-
brane bound matrix metalloproteinase capable of directly cleaving both type I collagen and fibrin but not by other, soluble
matrix metalloprotinases.These data convincingly demonstrate one way that tumor cells orchestrate proteolysis to invade
surrounding tissues.
